Novel prognostic biomarker TBC1D1 is associated with immunotherapy resistance in gliomas

Overview of attention for article published in Frontiers in immunology, March 2024

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (59th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter: 5 X users

Readers on

mendeley: 4 Mendeley

Summary X

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 42,143 followers.

RT @FrontImmunol: New Research: Novel prognostic biomarker TBC1D1 is associated with immunotherapy resistance in gliomas: Background Gliom…

13 Mar 2024

Reply Repost Favourite

RT @FrontImmunol: New Research: Novel prognostic biomarker TBC1D1 is associated with immunotherapy resistance in gliomas: Background Gliom…

11 Mar 2024

Reply Repost Favourite

RT @FrontImmunol: New Research: Novel prognostic biomarker TBC1D1 is associated with immunotherapy resistance in gliomas: Background Gliom…

11 Mar 2024

Reply Repost Favourite

New Research: Novel prognostic biomarker TBC1D1 is associated with immunotherapy resistance in gliomas: Background Glioma, an aggressive brain tumor, poses a challenge in understanding the mechanisms of treatment resistance, despite… https://t.co/50wvLAqt

11 Mar 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.